Carl H. June
University of Pennsylvania
Public scientific profile · Unclaimed
Built from public scholarly sources. Expertise is inferred by ScienceWe from publications and has not been confirmed by the scientist.
Top expertise
CAR-T cell therapy research
Strong evidence · 11 supporting papers · latest 2026
Calcium signaling and nucleotide metabolism
Strong evidence · 1 supporting paper · latest 2026
vaccines and immunoinformatics approaches
Solid evidence · 2 supporting papers · latest 2026
Immunotherapy and Immune Responses
Solid evidence · 5 supporting papers · latest 2026
Cutaneous lymphoproliferative disorders research
Solid evidence · 3 supporting papers · latest 2026
Virus-based gene therapy research
Solid evidence · 2 supporting papers · latest 2026
Immune Cell Function and Interaction
Solid evidence · 1 supporting paper · latest 2026
RNA Interference and Gene Delivery
Solid evidence · 1 supporting paper · latest 2026
Publications (13)
Decade-long persistence of CD19 CAR T cells in B cell lymphomas
2026DOIPMID 42575986
Enhanced anti-tumor efficacy through combined CAR T cell therapy and CD40 stimulation in syngeneic solid tumor models
2026DOI
T-cell immunosenescence limits CD19 CAR T-cell function in chronic lymphocytic leukemia
2026DOIPMID 42636161
A generalizable system for antigenic peptide targeting across HLA-I allotypes
2026DOIPMID 42239416
AI-driven discovery of GPNMB CAR T cells as a multi-cancer therapy
2026DOIPMID 42349383
Engineering a juxtamembrane-targeting CAR T-cell against mesothelin: a novel binder resilient to shed antigen for enhanced efficacy against ovarian and pancreatic cancer
2026DOIPMID 42459653
Multimodal analysis of CD38 in T-cell Acute Lymphoblastic Leukemia Identifies Combinatorial Therapeutic Strategies
2026DOIPMID 42685004
Kidney Transplantation in Two Highly Sensitized Candidates after CAR T-Cell Therapy
2026DOIPMID 42235014
Ten-Year Outcomes after CAR T-Cell Therapy for B-Cell Lymphomas
2026DOIPMID 42341302
HITE: HIV Inspired Lipid Nanoparticle Platform for CAR T Cell Engineering
2026DOIPMID 42012130
Updated overall survival, safety, and neurologic function outcomes from a phase 1 trial of bivalent chimeric antigen receptor (CAR) T cell therapy in recurrent glioblastoma (GBM).
2026DOI
A modular γδ TCR-T platform combining KRAS pMHC targeting with re-dosable mRNA engager redirection
2026DOIPMID 42681680
Publisher Correction: Decade-long persistence of CD19 CAR T cells in B cell lymphomas
2026DOIPMID 42649259
Organizations in sourced records
Affiliation evidence only — not confirmed current employment.
- University of Pennsylvania
Source: OpenAlex · retrieved 2026-09-29